Response and toxicity monitored during the treatment cycles of Diffuse Large B-cell Lymphoma (DLBCL) enable the physician to take the decision about the best treatment protocol. These differences in outcomes are related mainly to age, physiological status and genetic factors. Toxicity is a frequent outcome that may be developed from accumulation of the drug itself or its metabolites. Current study...